EKF vs. MXCT, CREO, IUG, NCYT, POLX, IHC, AVO, RUA, SUN, and MHC
Should you be buying EKF Diagnostics stock or one of its competitors? The main competitors of EKF Diagnostics include MaxCyte (MXCT), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), Surgical Innovations Group (SUN), and MyHealthChecked (MHC). These companies are all part of the "medical devices" industry.
EKF Diagnostics vs. Its Competitors
EKF Diagnostics (LON:EKF) and MaxCyte (LON:MXCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.
70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 70.5% of MaxCyte shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by insiders. Comparatively, 1.5% of MaxCyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, MaxCyte had 1 more articles in the media than EKF Diagnostics. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for EKF Diagnostics. MaxCyte's average media sentiment score of 0.28 beat EKF Diagnostics' score of 0.00 indicating that MaxCyte is being referred to more favorably in the news media.
EKF Diagnostics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
EKF Diagnostics received 174 more outperform votes than MaxCyte when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 68.92% of users gave MaxCyte an outperform vote.
EKF Diagnostics has a net margin of 9.37% compared to MaxCyte's net margin of -78.37%. EKF Diagnostics' return on equity of 7.03% beat MaxCyte's return on equity.
EKF Diagnostics has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
EKF Diagnostics beats MaxCyte on 9 of the 15 factors compared between the two stocks.
Get EKF Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EKF Diagnostics Competitors List
Related Companies and Tools
This page (LON:EKF) was last updated on 6/13/2025 by MarketBeat.com Staff
